Hepatitis C deaths up, baby boomers most at risk

February 20, 2012 By LAURAN NEERGAARD , AP Medical Writer in Diseases, Conditions, Syndromes

Hepatitis C deaths up, baby boomers most at risk (AP)

Enlarge

Graphic shows the expected outcomes per one hundred people infected with Hepatitis C

(AP) -- Deaths from liver-destroying hepatitis C are on the rise, and new data shows baby boomers especially should take heed - they are most at risk.

Federal health officials are considering whether anyone born between 1945 and 1965 should get a one-time blood test to check if their livers harbor this ticking time bomb. The reason: Two-thirds of people with hepatitis C are in this age group, most unaware that a virus that takes a few decades to do its damage has festered since their younger days.

The issue has taken new urgency since two drugs hit the market last summer that promise to cure many more people than ever was possible. And research published Monday says testing millions of the middle-aged to find those who need the pricey treatment would be worth the cost, saving thousands of lives.

"One of every 33 are living with ," says Dr. John Ward, hepatitis chief at the . "Most people will be surprised, because it's a silent epidemic."

Don't think you need to worry? Yes, sharing a needle while injecting is the biggest risk factor for becoming infected with this blood-borne virus. But before 1992, when widespread testing of the began, hepatitis C commonly was spread through blood transfusions. Plus, a one-time experiment with drugs way back in high school or college could have been enough.

"Asking someone about a risk that happened 20 to 30 years ago is a lot to ask," says Ward. Hence the quest for a new strategy.

About 3.2 million Americans are estimated to have , but at least half of them may not know it. The virus, which affects 170 million people worldwide, can gradually scar the liver and lead to cirrhosis or . It is a leading cause of .

A CDC study published Monday analyzed a decade of death records and found an increase in from hepatitis C. In fact, in 2007 there were 15,000 deaths related to hepatitis C, higher than previous estimates - and surpassing the nearly 13,000 deaths caused by the better-known AIDS virus.

Perhaps more surprising, three-fourths of the deaths occurred in the middle-aged, people 45 to 64, researchers reported in Annals of Internal Medicine.

"Mortality will continue to grow for the next 10 to 15 years at least unless we do something different" to find and treat the silent sufferers, Ward says.

CDC's current guidelines recommend testing people known to be at high risk, and until last summer there wasn't much enthusiasm even for that step: the reasons are the year-long, two-drug treatment promised to cure only 40 percent of people; treatment was so grueling that many patients refused to try it and treatment could cost up to $30,000.

Two new drugs - Vertex Pharmaceuticals' telaprevir and Merck & Co.'s boceprevir - are starting to change that pessimism. Research suggests adding one of them to standard therapy can boost cure rates as high as 75 percent. While still full of side effects, they can allow some people to finish treatment in just six months. They add to the price, however, another $1,000 to $4,000 a week. Drugs that promise to work even better have begun testing.

Those advances are fueling CDC deliberations of whether to change testing guidelines to recommend that anyone born between 1945 and 1965 get a one-time screening. A second CDC-funded study published Monday analyzed models of that option, and concluded it had the potential to save 82,000 lives.

A third study published Monday from Stanford University looked more closely at the price tag, and concluded the new triple-therapy would be cost-effective for people with advanced disease. It's still cheaper than a transplant costing well over $100,000. But not everyone with will go on to suffer serious damage. For those with mild disease, that analysis concluded some gene testing to predict who might really need the costlier triple therapy rather than the older drugs would be a good next step.

It's not clear how quickly the CDC will settle the boomer-screening question. But doctors at New York's Montefiore Medical Center have started raising the issue with boomers. And Montefiore internist Dr. Gary Rogg says a number of patients have sought testing after seeing hepatitis-awareness ads from the drugs' manufacturers.

"Now it's considered a curable disease, that makes all the difference," says Rogg, who was surprised at some longtime patients' test results. Even a nurse he knows learned she had it, and the only risk she could recall was a blood transfusion during surgery when she was 10 years old.

More information:
Online: Centers for Disease Control and Prevention: http://www.cdc.gov/

Montefiore Medical Center: http://bit.ly/u6scH0

©2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

not rated yet  

Filter


Move the slider to adjust rank threshold, so that you can hide some of the comments.


Display comments: newest first

ironjustice
Feb 21, 2012

Rank: not rated yet
Iron reduction therapy has been shown to be very effective.
"Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials."
"Normalization of Elevated Hepatic 8-Hydroxy-2'-Deoxyguanosine Levels in Chronic Hepatitis C Patients by Phlebotomy and Low Iron Diet"
"Effects of Dietary Iron Reduction Versus Phlebotomy in Patients with Chronic Hepatitis C: Results from a Randomized, Controlled Trial on 40 Japanese Patients."
"A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan."
"Maintenance Phlebotomy Slows Disease Progression in Patients with Chronic Hepatitis C"
"Hepatocellular carcinoma caused by iron overload: A possible mechanism of direct hepatocarcinogenicity".

ironjustice
Feb 21, 2012

Rank: not rated yet
Iron reduction therapy has been shown to be very effective.
"Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials."
"Normalization of Elevated Hepatic 8-Hydroxy-2'-Deoxyguanosine Levels in Chronic Hepatitis C Patients by Phlebotomy and Low Iron Diet"
"Effects of Dietary Iron Reduction Versus Phlebotomy in Patients with Chronic Hepatitis C: Results from a Randomized, Controlled Trial on 40 Japanese Patients."
"A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan."
"Maintenance Phlebotomy Slows Disease Progression in Patients with Chronic Hepatitis C"
"Hepatocellular carcinoma caused by iron overload: A possible mechanism of direct hepatocarcinogenicity".

AnyLabTestNow
Feb 25, 2012

Rank: not rated yet
Screening for Hepatitis C is very easy. It is a simple and inexpensive blood test.

It is $49.00 at ANY LAB TEST NOW and you will have results next day!!!

You can do it on your own without the doctor's prescription.
Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

WHO: Scientific red tape mars efforts vs. virus

International efforts to combat a new pneumonia-like virus that has now killed 22 people are being slowed by unclear rules and competition for the potentially profitable rights to disease samples, the head ...

Diseases, Conditions, Syndromes created 5 minutes ago | popularity not rated yet | comments 0

Shortage of key drug hampering U.S. efforts to control TB, report says

(HealthDay)—A shortage of a critical tuberculosis drug has hampered the efforts of health departments across the United States to contain the spread of the highly infectious lung disease, federal officials ...

Diseases, Conditions, Syndromes created 45 minutes ago | popularity not rated yet | comments 0

Heart healthy lifestyle may cut kidney disease patients' risk of kidney failure

Maintaining a heart healthy lifestyle may also help protect chronic kidney disease patients from developing kidney failure and dying prematurely, according to a study appearing in an upcoming issue of the Journal of the Am ...

Diseases, Conditions, Syndromes created 1 hour ago | popularity not rated yet | comments 0

Flu vaccine also linked to narcolepsy in adults, study reports

Finnish researchers unveiled new data Thursday to link the Pandemrix flu vaccine to a higher risk of the sleeping disorder narcolepsy in adults.

Diseases, Conditions, Syndromes created 1 hour ago | popularity not rated yet | comments 0

Second child contracts polio in Pakistan's Waziristan

A second child has contracted polio in a restive Pakistani tribal region near the Afghan border after the Taliban banned vaccinations there nearly a year ago, a UN official said Thursday.

Diseases, Conditions, Syndromes created 1 hour ago | popularity not rated yet | comments 0


Controlling mood through the motions of mitochondria

(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...

Future doctors unaware of their obesity bias

Two out of five medical students have an unconscious bias against obese people, according to a new study by researchers at Wake Forest Baptist Medical Center. The study is published online ahead of print in the Journal of ...

Research identifies a way to make cancer cells more responsive to chemotherapy

Breast cancer characterized as "triple negative" carries a poor prognosis, with limited treatment options. In some cases, chemotherapy doesn't kill the cancer cells the way it's supposed to. New research from Western University ...

Mayo Clinic genomic analysis lends insight to prostate cancer

Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings ...

Merck ends development of Parkinson's disease drug

(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.

New microsphere-based methods for detecting HIV antibodies

Detection of HIV antibodies is used to diagnose HIV infection and monitor trials of experimental HIV/AIDS vaccines. New, more sensitive detection systems being developed use microspheres to capture HIV antibodies ...